Submission of voting results of 31st Annual General Meeting of the Company under Regulation 44(3) of the SEBI (listing Obligations & Disclosure Requirements) Regulations, 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd submitted the voting results of its 31st Annual General Meeting held on December 31, 2025 at 09:00 AM. All 6 resolutions were passed unanimously with 100% votes in favour and zero votes against. A total of 28 members holding 14,07,959 equity shares (of Rs. 10 face value) cast valid votes, out of 2,584 eligible shareholders as on the cut-off date of December 24, 2025. The resolutions covered adoption of FY25 audited financial statements, re-appointment of Ms. Parul Agrawal as director (by rotation), appointment of Secretarial Auditors for five years, regularization of Mr. Yogainder Kumar Gupta as Independent Director, re-appointment of Mr. Yogesh Agrawal as Chairman & Managing Director for 5 years, and alteration of the Object Clause of the MOA.
The unanimous approval indicates strong promoter control and no shareholder dissent on key governance matters. However, very low voting turnout (only ~1.08% of shareholders participated) suggests limited retail interest or a closely-held company structure. The MOA object clause change and CMD re-appointment signal continuation of existing business direction under current management.